Regenxbio's Multi-Catalyst Setup Is Hard To Ignore (Rating Upgrade)

Regenxbio Inc. delivered a strong quarter, driven by milestone revenue, with GAAP EPS of $0.43 and revenue up 407% YoY. RGNX now holds $313 million in pro forma cash, funding operations into Q4 2027 and removing near-term financing overhang. Multiple late-stage catalysts—including RGX-202, pivotal wet AMD data, and RGX-121 resubmission—are stacked over the next 12–18 months.

Seeking Alpha • Aug 11, 2026

REGENXBIO Q2 Earnings Call Highlights

REGENXBIO NASDAQ: RGNX reported second-quarter 2026 progress across its late-stage gene-therapy pipeline, highlighting completed enrollment in its Duchenne muscular dystrophy confirmatory study, an agreed path to resubmit its Hunter syndrome therapy application, and the start of a pivotal diabetic retinopathy study under its AbbVie collaboration.

MarketBeat • Aug 7, 2026

REGENXBIO Inc. (RGNX) Q2 2026 Earnings Call Transcript

REGENXBIO Inc. (RGNX) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 6, 2026

REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights

RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q3 2026 initiation, with potential accelerated approval in 2H 2027 Long-term surabgene lomparvovec (sura-vec, ABBV-RGX-314) data highlight durable safety and efficacy profile ahead of key catalyst Topline data from pivotal subretinal wet AMD studies, ATMOSPHERE ® and ASCENT ®**, expected in Q4 2026 Phase IIb/III NAAVIGATE trial for diabetic retinopathy ongoing Reaffirmed path forward for RGX-121 for Hunter syndrome with FDA during productive July Type A meeting; resubmission on track for Q3 2026 Over $200 million new capital in July 2026 extends cash runway into Q4 2027 Pro forma ending Q2 2026 cash, cash equivalents and marketable securities in excess of $310 million Webcast today at 8:00 a.m. ET ROCKVILLE, Md.

PRNewsWire • Aug 6, 2026

Regenxbio (RGNX) Beats Q2 Earnings and Revenue Estimates

Regenxbio (RGNX) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to a loss of $1.38 per share a year ago.

Zacks Investment Research • Aug 6, 2026

REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights

ROCKVILLE, Md., Aug. 3, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, August 6, at 8:00 a.m.

PRNewsWire • Aug 3, 2026

New Strong Sell Stocks for July 23rd

ABR, ARDX and RGNX have been added to the Zacks Rank #5 (Strong Sell) List on July 23, 2026.

Zacks Investment Research • Jul 23, 2026

Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm

NEW YORK, July 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Regenxbio, Inc. (NASDAQ: RGNX) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Regenxbio, Inc. provided investors with false and/or misleading information regarding the efficacy and safety of its trial study for RGX-111, a one-time gene therapy for the treatment of Hurler Syndrome, including positive assertions of RGX-111's future trial success based on continuing positive biomarker and safety data from the ongoing PhaseI/II study.

PRNewsWire • Jul 21, 2026

Clinical Trial Results Show Extended Benefits for REGENXBIO Retinal Treatments

REGENXBIO Inc. (NASDAQ:RGNX) on Saturday shared long-term clinical trial findings for its experimental gene therapy surabgene lomparvovec (sura-vec, ABBV-RGX-314) targeting wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR).

Benzinga • Jul 20, 2026

REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting

One-time gene therapy treatment with sura-vec demonstrated long-term efficacy at similar doses to those being evaluated in ongoing late-stage studies: Stable to improved vision through 5 years in wet AMD patients who required frequent anti-VEGF injections prior to one-time sura-vec; no drug-related IOI observed in a setting of no prophylactic steroids Prevention of vision-threatening events without any additional treatment and > 2-step DRSS improvement in majority of NPDR participants at 2.5 years; no IOI observed with short-course prophylactic topical steroids Topline data from wet AMD pivotal studies, ATMOSPHERE® and ASCENT®, expected in Q4 2026 ROCKVILLE, Md.,, July 18, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced positive data from long-term follow-up studies of investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314) in wet AMD using subretinal delivery and diabetic retinopathy (DR) using suprachoroidal delivery.

PRNewsWire • Jul 18, 2026